Απρίλιος 2013

A pan-European strategy and platform is being implemented for translational cancer research. With 25 % of all deaths in the EU resulting from cancer, combating this disease more effectively has become a top priority.

In the field of cancer research, Europe has the building blocks to convert scientific discoveries and inventions into innovative products and services. However, the fragmentation and duplication of research efforts is strongly impairing the implementation of new discoveries in clinical applications.

Cutting-edge equipment combined with advanced faculty training has enabled one German university to become a global player in the evolving field of neuroscience.

Neuroscience, the scientific study of the nervous system, is considered an interdisciplinary science that interfaces with other fields such as mathematics, medicine, linguistics, computer science, physics and psychology. The Ernst Moritz Arndt University of Greifswald, one of Europe's noblest and oldest universities in Germany's north-eastern region, aimed to enhance its research capabilities in neuroscience.

Large-scale genomic analysis of renal cell carcinoma combined with clinical and epidemiological information would address the need for disease molecular markers. This could potentially lead to new diagnostic tools and the design of targeted treatments.

The incidence of renal cell carcinoma has been increasing in Europe over the past two decades. In certain parts of Europe the disease is particularly prevelant and it therefore presents serious health concerns in these areas.